Scholars@Duke publication: Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

Publication , Journal Article

Hurwitz, H; Douglas, PS; Middleton, JP; Sledge, GW; Johnson, DH; Reardon, DA; Chen, D; Rosen, O

Published in: JOURNAL OF CLINICAL ONCOLOGY

May 20, 2010

JOURNAL OF CLINICAL ONCOLOGY

1527-7755

0732-183X

May 20, 2010

AMER SOC CLINICAL ONCOLOGY

APA

Chicago

ICMJE

MLA

NLM

Hurwitz, H., Douglas, P. S., Middleton, J. P., Sledge, G. W., Johnson, D. H., Reardon, D. A., … Rosen, O. (2010). Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). JOURNAL OF CLINICAL ONCOLOGY, 28(15).

Hurwitz, H., P. S. Douglas, J. P. Middleton, G. W. Sledge, D. H. Johnson, D. A. Reardon, D. Chen, and O. Rosen. “Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).” JOURNAL OF CLINICAL ONCOLOGY 28, no. 15 (May 20, 2010).

Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). JOURNAL OF CLINICAL ONCOLOGY. 2010 May 20;28(15).

Hurwitz, H., et al. “Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).” JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 15, AMER SOC CLINICAL ONCOLOGY, May 2010.

Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2010 May 20;28(15).

JOURNAL OF CLINICAL ONCOLOGY

1527-7755

0732-183X

May 20, 2010

AMER SOC CLINICAL ONCOLOGY